Weed (BUDZ) Asset Writedowns and Impairment (2019)
Weed (BUDZ) posted quarterly Asset Writedowns and Impairment of $499695.0 for Q4 2019.
Weed (BUDZ) Asset Writedowns and Impairment (2019) Analysis & Trends
Weed's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $499695.0 for Q4 2019.
- In Q4 2019, Asset Writedowns and Impairment changed N/A year-over-year to $499695.0; the TTM figure through Sep 2020 stood at $499695.0 (changed N/A YoY), while the FY2019 annual figure was $499695.0, up 55.37% from the prior year.
- Asset Writedowns and Impairment for Q4 2019 stood at $499695.0.
- The five-year high for Asset Writedowns and Impairment was $499695.0 in Q4 2019, with the low at $499695.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Weed | 2.88 Mn | 2.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 499,695.00 |
| Dec 31, 2019 | 499,695.00 |